ISRG— AI Stock Forecast & Price Targets
Published 8/16/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ISRG price forecast →
Intuitive Surgical's near-term volatility stems from product recall concerns and weak momentum, but strong fundamentals, expanding service lines, and a favorable forecast band suggest resilience. Valuation remains elevated, requiring patience for catalysts to validate growth expectations.
Hold near $394.51; invalidation below $328.57 (52W low). Monitor for confirmation of QoQ growth rebound or earnings beat to validate momentum.
Accumulate if price breaks above $425.00 with sustained volume, targeting $485.41 (Kronos forecast). Catalysts include resolution of recalls and continued da Vinci 5 adoption growth; failure to meet Q3 EPS expectations would trigger trimming.
Terminal thesis: dominant position in robotic surgery with expanding service lines. Structural risk is regulatory shifts or pricing pressure, but long-term growth potential remains strong given market leadership and margin resilience.
Revenue shows steady growth (18.54% QoQ), supported by strong gross margins (66.67%) and operating margins (31.28%). Free cash flow is robust ($2.6B) with healthy balance sheet strength (current ratio 4.96, debt-to-equity 0). However, near-term headwinds from product recalls and weak procedure growth (Q2 US procedure growth slowed) threaten momentum. Capital allocation prioritizes R&D over buybacks, which is sustainable given cash flow but may limit upside in the short term.
The chart shows a downtrend with recent support at $394.51 (current price), while resistance lies near $425.00 and $485.41 (forecast bands). The Kronos AI forecast band suggests potential upside to $485.41, but the 24h drop of 1.69% indicates short-term volatility. RSI at 55.87 suggests neutral momentum, with technicals aligning with fundamental resilience but requiring catalyst confirmation.
Recent news highlights near-term challenges: product recalls and slowed US procedure growth (Q2), though long-term moats remain intact. The Oppenheimer upgrade to 'Outperform' provides positive sentiment, while the $479.86 target price from analysts suggests confidence in recovery. However, the 17.5% loss over six months underscores recent volatility and valuation concerns.
- da Vinci 5 adoption continues to drive revenue growth (Q2 US procedure growth slowed but underlying demand remains strong)
- Ion endoluminal system expansion into diagnostic procedures diversifies revenue streams
- Product recalls threaten near-term adoption rates and revenue visibility
- High valuation multiples (forward P/E 32.68) leave limited room for error on earnings misses.
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord